The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Model-driven metronomic vinorelbine in heavily pre-treated metastatic NSCLC and PM patients: Results of a phase I/II study.
 
Joseph Ciccolini
Honoraria - Ipsen; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Merck Serono
 
Elissa Cousin
No Relationships to Disclose
 
Laure Deyme
No Relationships to Disclose
 
Diane-Charlotte Imbs
No Relationships to Disclose
 
Sylvanie Bonnet
No Relationships to Disclose
 
Raphael Serre
No Relationships to Disclose
 
Matthieu Barbolosi
No Relationships to Disclose
 
Laurent Greiller
No Relationships to Disclose
 
Pascale Tomasini
No Relationships to Disclose
 
Melissa Galloux
No Relationships to Disclose
 
Bruno Lacarelle
No Relationships to Disclose
 
Dominique Barbolosi
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Ignyta (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)